Proteome Sciences plc
(the "Company" or the "Group")
Director Dealing and Total Voting Rights
Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") respectively.
Application has been made to the London Stock Exchange for the 323,891 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 18 April 2017.
After Admission, the total number of Ordinary Shares in issue will be 294,648,723, all with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information: Proteome Sciences plc |
Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)1932 865065 |
Dr Ian Pike, Chief Scientific Officer |
|
Geoff Ellis, Finance Director |
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson |
Tel: +44 (0)20 7220 0500 |
Tony Quirke (broking) IFC Advisory (Financial PR and IR) |
Tim Metcalfe/Graham Herring/Miles Nolan |
Tel: +44 (0)20 3053 8671 |
|
|
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.
1. |
Details of the person discharging managerial responsibilities / person closely associated |
a) |
Name |
Ian Pike |
2. |
Reason for the Notification |
a) |
Position/status |
Chief Scientific Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Proteome Sciences plc |
b) |
LEI |
n/a |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the Financial instrument, type of instrument |
Options over Ordinary Shares of 1p each |
Identification code |
GB0003104196 |
b) |
Nature of the transaction |
Exercise of options |
c) |
Price(s) and volume(s) |
165,583 options |
d) |
Aggregated information: · Aggregated volume · Price |
165,583 Options over Ordinary Shares of 1p each exercised |
e) |
Date of the transaction |
7 April 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
